12 October 2020
To compare the bioequivalence of two formulations of valsartan (80 mg capsules) under fasting and fed conditions in healthy Chinese volunteers using a full-replicate study design.
A total of 78 Subjects were randomly assigned to fasting cohort (n = 48) or fed cohort (n = 30). Each cohort includes 4 single-dose observation periods and 3-day washout periods. Blood samples were collected at designed time point. Plasma concentration of valsartan was analyzed by a validated LC-MS/MS method. Noncompartmental analysis method was employed to determine the pharmacokinetic parameters. Based on the within-subject standard deviation (S WR) of the reference formulation, either reference-scaled average bioequivalence (RSABE) or average bioequivalence (ABE) method was used to evaluate the bioequivalence of the two formulations.
Under fasting conditions, the RSABE method was used to evaluate the bioequivalence of C max (S WR>0.294), while ABE method was used to evaluate the bioequivalence of AUC 0-t and AUC 0-∞. The geometric mean ratio (GMR) of the test/reference for C max was 99.52%, and the 95% upper confidence bound was <0. For AUC 0-t and AUC 0-∞ comparisons, GMRs were 102.07% and 101.92%, and the 90% CIs of the test/reference were 96.28%–108.21%, 96.28%–107.88%, respectively. Under fed conditions, the S WR value of C max, AUC 0-t and AUC 0-∞ all exceeded the cutoff value of 0.294 and therefore, the RSABE method was used. The GMRs for C max, AUC 0-t and AUC 0-∞ were 98.78%, 103.33% and 103.08%, respectively, while the 95% upper confidence bound values were all <0. These results all met the bioequivalence criteria for highly variable drugs. All adverse events were mild and transient.
In this study, the generic formulation of valsartan 80 mg capsule was considered to be bioequivalent to the reference product under both fasting and fed conditions, and satisfied the requirements for marketing in China.